Caffeine pharmacokinetics during hyperbaric hyperoxia in humans | Canada Hyperbarics Skip to main content
Study Aviat Space Environ Med 1997

Caffeine pharmacokinetics during hyperbaric hyperoxia in humans

Rump A, Siekmann U, Dreja M, Kalff G — Aviat Space Environ Med, 1997

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

Researchers investigated how hyperbaric oxygen therapy affects the way the human body processes caffeine in two healthy volunteers.

What They Found

The study found that caffeine's pharmacokinetic parameters, such as its peak concentration (Cmax) and elimination half-life (T1/2), were similar to established normal values. For example, Volunteer 1 had a Cmax of 6.13 mg/L and T1/2 of 180 minutes, while Volunteer 2 had a Cmax of 6.23 mg/L and T1/2 of 283 minutes. Statistical tests showed no significant changes in caffeine processing during 110 minutes of hyperbaric oxygen at 2.5 ATA, alternating 100% oxygen and air breathing.

Canadian Relevance

No direct Canadian connection identified.

Study Limitations

A significant limitation of this study is its very small sample size, involving only two human volunteers.

Was this summary helpful?

Study Details

Study Type Study
Category Uncategorised
Source Pubmed
PubMed ID 9125091
Year Published 1997
Journal Aviat Space Environ Med
MeSH Terms Adult; Biological Availability; Caffeine; Drug Monitoring; Humans; Hyperbaric Oxygenation; Intestinal Absorption; Male; Metabolic Clearance Rate; Time Factors; Tissue Distribution

Cite This Study

Share

Find a Canadian Clinic Treating Uncategorised

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.